Sat, Oct 25, 2014, 6:27 PM EDT - U.S. Markets closed

Recent

% | $
Quotes you view appear here for quick access.

Exelixis, Inc. Message Board

  • wilderguide wilderguide Jul 26, 2013 9:09 PM Flag

    Cabo in post-Sorafenib HCC

    $$$$
    Finally got posted at clnicaltrialsdotgov
    NCT01908426
    Least MMM'll have some fresh material to chat at the ER.
    Upward & onward. Uh-huh...I said upward...
    GLTA

    SortNewest  |  Oldest  |  Most Replied Expand all replies
    • $$$$
      I went looking to get current on the state of sorafenib therapy and found a good read I'd like to recommend to all. Published online in the World Journal of Hepatology, 7/27/13:
      "Mechanisms of Resistance to Sorafenib and the corresponding strategies in HCC"

      Good piece on current state of research toward mediating sorafenib resistance, with good analysis of the P2 results of high-MET, 2nd line HCC, tivantinib-treated patient pops. Might provide a good preview of the analytics we might find in Cabo's post- Nexavar "Celestial" trial that should be recruiting next month, and I think will be discussed at length at the coming ER. Good informative read for those looking to understand the strategy of Cabo's pending P3 trial. Commentary invited...
      GLTA
      .

 
EXEL
1.69+0.05(+3.05%)Oct 24 3:59 PMEDT

Trending Tickers

i
Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.
Amazon.com Inc.
NasdaqGSFri, Oct 24, 2014 4:00 PM EDT
Digital River Inc.
NasdaqGSFri, Oct 24, 2014 4:00 PM EDT